Inflammatory myopathies

Increased serum level of IL-6 predicts poor prognosis in anti-MDA5-positive dermatomyositis with rapidly progressive interstitial lung disease

Arthritis Res TherPublished Retrospective cohort study

Authors' conclusion

Our study demonstrated that increased level of serum IL-6 (≥ 13.41pg/mL) and severe lymphopenia were promising predictors of 6-month all-cause mortality and the occurrence of RP-ILD in anti-MDA5-positive DM patients.

Study context

Population
Patients with anti-MDA5-positive DM (with rapidly progressive interstitial lung disease (RP-ILD)), two cohorts
Participants
168 patients2 cohorts
Exposure
Group 1 vs Group 2 vs Group 3
Outcome
Predictors of 6-month all-cause mortality and RP-ILD
Follow-up
6 months
Methodological detailstwo cohorts, univariate and multivariate Cox regression, group-based trajectory modeling
  • Two cohorts
  • Univariate and multivariate Cox regression
  • Group-based trajectory modeling

Main finding

As reported in the abstract

Independent predictors (multivariate Cox regression)
  • Independent predictors of 6-month all-cause mortality: IL-6 ≥ 13.41pg/mL, lymphocytes < 0.5 × 109 /L, lymphocytes 0.5 to 1.0 × 109 /L, older age, elevated LDH
  • Independent predictors of RP-ILD: IL-6 ≥ 13.41pg/mL, lymphocytes < 0.5 × 109 /L, lymphocytes 0.5 to 1.0 × 109 /L

Observational data: associations, not effects.

Further findings

Mortality by lymphocyte trajectory group (first week after admission) — Group 1
90.7%

Mortality by lymphocyte trajectory group (first week after admission)

Group 1 showed the highest mortality, all experiencing RP-ILD

Lung tissue findings

Increased IL-6 expression in lung tissue in two cases with RP-ILD vs two without
Increased infiltration of CD4+ and CD8+ T cells, particularly CD8+, in lung tissue with RP-ILD

Original publication

Increased serum level of IL-6 predicts poor prognosis in anti-MDA5-positive dermatomyositis with rapidly progressive interstitial lung disease. Arthritis Res Ther. Published 28 October 2024. doi:10.1186/s13075-024-03415-5

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.